| A292 |
Vatelizumab Biosimilar(Anti-Integrin a2b1 (ITGA2 & ITGB1) Reference Antibody )
Featured
|
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis. |
|
| A294 |
Etaracizumab Biosimilar(Anti-Integrin aVb3 (ITGAV & ITGB3) Reference Antibody )
Featured
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer. |
|
| A295 |
Orilanolimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity. |
|
| DC60663 |
Si5-N14
Featured
|
Si5-N14 is a lipid-based molecule engineered with siloxane groups, designed specifically for efficient mRNA delivery to the lungs. The incorporation of siloxane units boosts the cellular uptake of mRNA-loaded lipid nanoparticles (LNPs) and enhances their ability to escape from endosomes. These properties significantly increase the overall effectiveness of mRNA delivery, making Si5-N14 a promising tool for targeted therapeutic applications. |
|
| DC60665 |
JNJ-74856665
Featured
|
JNJ-74856665 is an orally bioavailable, potent, and selective DHODH inhibitor with IC50 of 0.40 nM. JNJ-74856665 shows favorable physicochemical properties and has been selected for clinical development in patients with AML and myelodysplastic syndromes (MDS). |
|
| DC60666 |
JAB-3312
Featured
|
JAB-3312 is a potent SHP2 allosteric inhibitor with binding Kd of 0.37 nM, enzymatic IC50 of 1.9 nM, KYSE-520 antiproliferative IC50 of 7.4 nM and p-ERK inhibitory IC50 of 0.23 nM, respectively. |
|
| DC60667 |
EDP-235
Featured
|
EDP-235 is a SARS-CoV-2 3CLpro inhibitor with potent nanomolar activity against all SARS-CoV-2 variants, as well as clinically relevant human and zoonotic coronaviruses. EDP-235 maintains potency against variants bearing mutations associated with nirmatrelvir resistance. EDP-235 demonstrates a ≥ 500-fold selectivity index against multiple host proteases. |
|
| DC60668 |
BI-9787
Featured
|
BI-9787 is a potent zwitterionic ketohexokinase inhibitor with nanomolar activity against hKHK-C, hKHK-A, mKHK-C and rKHK-C. BI-9787 shows >100-fold selectivity for all targets except PDE4D2. |
|
| DC60669 |
YD23
Featured
|
YD23 is a potent and highly selective degrader of SMARCA2. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts. |
|
| A296 |
Efalizumab Biosimilar(Anti-Integrin aL / ITGAL / CD11a Reference Antibody)
Featured
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research. |
|
| A297 |
Abituzumab Biosimilar（Anti-Integrin aV / ITGAV / CD51 Reference Antibody）
Featured
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer. |
|
| A298 |
Intetumumab Biosimilar（Anti-Integrin aV / ITGAV / CD51 Reference Antibody）
Featured
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer. |
|
| A299 |
Tadocizumab Biosimilar（Anti-Integrin a2b3 (ITGA2 & ITGB3) Reference Antibody）
Featured
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. |
|
| A300 |
OS2966 Biosimilar（Anti-Integrin b1 / ITGB1 / CD29 Reference Antibody）
Featured
|
|
|
| A301 |
Erlizumab Biosimilar（Anti-Integrin b2 / ITGB2 / CD18 Reference Antibody）
Featured
|
|
|
| A302 |
Genentech patent anti-Integrin β7 Biosimilar（Anti-Integrin b7 / ITGB7 Reference Antibody）
Featured
|
|
|
| A303 |
ADCT-901 Biosimilar（Anti-KAAG1 Reference Antibody）
Featured
|
|
|
| A304 |
ADCT-901-MMAE Biosimilar(Anti-KAAG1 Reference Antibody)
Featured
|
|
|
| A305 |
Macrogenics patent anti-KID3 Biosimilar(Anti-KID3 Reference Antibody)
Featured
|
|
|
| A306 |
Lirilumab Biosimilar(Anti-KIR Reference Antibody)
Featured
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. |
|
| A307 |
Innate patent anti-KIR2DL Biosimilar(Anti-KIR2DL1 / CD158a Reference Antibody)
Featured
|
|
|
| A308 |
Lacutamab Biosimilar(Anti-KIR3DL2 / CD158k Reference Antibody)
Featured
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma. |
|
| A309 |
JNJ-69086420 Biosimilar(Anti-KLK2 / Kallikrein 2 Reference Antibody)
Featured
|
|
|
| A310 |
Genentech patent anti-KLK5 Biosimilar(Anti-KLK5 / Kallikrein 5 Reference Antibody )
Featured
|
|
|
| A311 |
NGM313 Biosimilar(Anti-Klotho Beta Reference Antibody)
Featured
|
|
|
| A312 |
RG7992 Biosimilar(Anti-Klotho Beta Reference Antibody)
Featured
|
|
|
| A313 |
Fianlimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
|
| A314 |
Favezelimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
|
| A315 |
Ieramilimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. |
|
| A316 |
Encelimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft). |
|
